Business Context and Reporting Period
This Form 8-K filing by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) reports on the results of the 2022 Annual Meeting of Stockholders held on June 15, 2022. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol SLRX.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting outcomes.
Material Changes and Voting Results
Four proposals were submitted to stockholders. The results were as follows:
- Election of Directors: Two Class I directors, Arnold Hanish and William McVicar, were elected. Both received over 23 million votes "For" with approximately 2.7 million votes "Withheld."
- Reverse Stock Split: Stockholders approved an amendment to the certificate of incorporation to effect a reverse stock split. The proposal received 30,862,704 votes "For" versus 5,392,071 votes "Against."
- Executive Compensation (Say-on-Pay): The non-binding advisory vote on executive compensation was approved with 21,233,396 votes "For" and 3,960,694 votes "Against."
- Auditor Ratification: The appointment of Ernst & Young LLP as independent auditors for the 2022 fiscal year was ratified with 34,483,859 votes "For" and 1,433,904 votes "Against."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Investor Verification Checklist
- Verify the implementation timeline and ratio of the approved reverse stock split.
- Confirm the effective date of the new Class I directors' terms.
- Review the full Proxy Statement for details on the executive compensation package that was voted upon.
- Check subsequent filings for the updated share count following the reverse stock split.